RDY - Dr.Reddy's Laboratories Ltd

RDY Stock Chart

RDY Profile

Dr. Reddy's Laboratories Limited, alongside its subsidiaries, operates globally as an integrated pharmaceutical firm. The company is structured into several segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. Within the Global Generics segment, Dr. Reddy's manufactures and markets a wide range of prescription and over-the-counter pharmaceutical products, both under its own brand names and as generic equivalents with therapeutic parity to branded formulations. This segment also includes a burgeoning biologics business.

The PSAI segment focuses on the production and sale of active pharmaceutical ingredients (APIs) and intermediates, pivotal components in the manufacture of finished pharmaceutical goods. Additionally, PSAI offers contract research services and custom manufacturing of APIs and steroids tailored to customer specifications. Dr. Reddy's Proprietary Products segment is dedicated to advancing innovative formulations through intensive research and development efforts.

In therapeutic domains spanning gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, the company's diversified portfolio underpins its global presence. Dr. Reddy's also explores cutting-edge therapies, particularly in oncology and inflammation, highlighting its commitment to advancing medical treatment paradigms. Notably, the company collaborates with Curis, Inc. in a strategic partnership aimed at discovering and commercializing small molecule antagonists targeting immuno-oncology and precision oncology indications.

Founded in 1984 and headquartered in Hyderabad, India, Dr. Reddy's Laboratories Limited continues to drive pharmaceutical innovation, leveraging its extensive expertise to meet global healthcare needs and enhance patient outcomes through groundbreaking research and development initiatives.

RDY Revenue Chart

RDY Earnings